Biologyarticle2026-11-10

Prospective and genetic analyses implicate lower immunosurveillance in the aetiology of prostate cancer

Open access0 citations

Abstract

Abstract Tumour-promoting inflammation and immune evasion are key features of cancer, but prospective evidence linking specific immune pathways to prostate cancer risk remains limited. Here we show that circulating proteins involved in immune regulation may influence prostate cancer development. We analyse 368 immune- and inflammation-related proteins measured in blood samples from men in the European Prospective Investigation into Cancer and Nutrition (EPIC), including 1434 cases and matched controls, and combine these results with data from UK Biobank. While no proteins are associated with risk in EPIC alone after multiple testing correction, meta-analysis identifies several proteins linked to prostate cancer risk, including IL15 and FLT3LG, in particular, in blood taken long before diagnosis. Higher levels of immune surveillance-related proteins, particularly those involved in natural killer and T cell activity, are associated with lower prostate cancer risk, whereas genetic evidence implicates PARP1, SPINT2 and NME3 in increased risk. These findings suggest that immune pathways play a role in prostate cancer development and highlight potential targets for prevention.

// Source

View paper (DOI)Open access versionOpenAlexNature CommunicationsPublished 2026-11-10

Authors: Mahboubeh Parsaeian, Wing Ching Chan, Joshua Atkins, Keren Papier, Marie Breeur, Trishna A. Desai, Zhe Huang, Chibuzor Franklin Ogamba, David Daniel Bogumil, Jiayi Shen, Malcolm J. W. Sim, Konstantinos K. Tsilidis, James Yarmolinsky, Sabina Rinaldi, Rudolf Kaaks, Verena Katzke, Matthias Bernd Schulze, Catarina Schiborn, Saverio Caini, Lorenzo Milani, Raúl Zamora-Ros, Marcela Guevara, Maria-Jose Sánchez, Maria-Dolores Chirlaque, Pilar Amiano, Rosalind A. Eeles, Christopher A. Haiman, Zsofia Kote-Jarai, Fredrick R. Schumacher, S. Benlloch, Ali Amin Al Olama, Kenneth R. Muir, Sonja I. Berndt, David V. Conti, Fredrik Wiklund, Stephen Chanock, Ying Wang, Catherine M. Tangen, Jyotsna Batra, Judith Ann Clements, APCB BioResource (Australian Prostate Cancer BioResource), Henrik Grönberg, Nora Pashayan, Johanna Schleutker, Demetrius Albanes, Stephanie Weinstein, Alicja Wolk, Catharine M. L. West, Lorelei Ann Mucci, Géraldine Cancel‐Tassin, Stella Koutros, Karina Dalsgaard Sørensen, Eli Marie Grindedal, David E Neal, Freddie C. Hamdy, Jenny L. Donovan, Robert J. Hamilton, Sue A. Ingles, Barry S. Rosenstein, Yongjie Lu, Graham G. Giles, Robert J. MacInnis, Adam S. Kibel, Ana Vega, M Kogevinas, Kathryn L Penney, Jong Y. Park, Janet L. Stanford, Cezary Cybulski, Børge G Nordestgaard, Sune F. Nielsen, Hermann Brenner, Christiane Maier, Jeri Kim, Esther M. John, Manuel Rodrigues Teixeira, Susan L. Neuhausen, Kim De Ruyck, Azad Razack, Lisa F. Newcomb, Davor Lessel, Radka Kaneva, Nawaid Usmani, Frank Claessens, Paul A. Townsend, Jose Esteban Castelao, Monique J. Roobol, Florence Menegaux, Kay-Tee Khaw, Lisa Cannon-Albright, Hardev Pandha, Stephen N. Thibodeau, David J. Hunter, Peter Kraft, William J. Blot, Tim J Elliott, Ian Geoffrey Mills, Elio Ríboli, L. Le Marchand

Institutions: Brigham and Women's Hospital, University of Washington, University of Alberta, Karolinska Institutet, Icahn School of Medicine at Mount Sinai, Universidade do Porto, Imperial College London, The University of Melbourne, Harvard University, KU Leuven, University of Oxford, University of Bristol, University of Manchester, University of Toronto, Turku University Hospital, University of Southern California, Ghent University, University College London, University of Copenhagen, Case Western Reserve University, Monash University, University of Ioannina, The University of Texas MD Anderson Cancer Center, Queen's University Belfast, Barcelona Institute for Global Health, University of Utah, Stanford University, Sorbonne Université, Copenhagen University Hospital, University of Cambridge, University of Turku, Stanford Medicine, German Cancer Research Center, Uppsala University, Manchester Academic Health Science Centre, Aarhus University, Aarhus University Hospital, University Medical Center Hamburg-Eppendorf, University of Surrey, Monash Health, National Cancer Institute, Erasmus MC, Cancer Research UK, Assistance Publique – Hôpitaux de Paris, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Queensland University of Technology, Institut d'Investigació Biomédica de Bellvitge, Biogipuzkoa Health Research Institute, Institut Català d'Oncologia, Instituto Murciano de Investigación Biosanitaria, University of Turin, Princess Margaret Cancer Centre, Queen Mary University of London, Universitat Pompeu Fabra, Municipal Institute for Medical Research, University of Potsdam, Université Paris-Saclay, University of Malaya, Mayo Clinic, Moffitt Cancer Center, Royal Marsden NHS Foundation Trust, City of Hope, Medical University of Sofia, NIHR Manchester Biomedical Research Centre, Colorado School of Public Health, Vanderbilt University Medical Center, Oslo University Hospital, Deutsches Konsortium für Translationale Krebsforschung, National Center for Tumor Diseases, University Hospitals of Cleveland, Institute of Cancer Research, Instituto de Investigación Sanitaria de Santiago, Gentofte Hospital, Pomeranian Medical University, Herlev Hospital, University Hospital Complex Of Vigo, Basque Government, Division of Cancer Epidemiology and Genetics, Universidad de Murcia, Instituto de Investigación Biosanitaria de Granada, Instituto de Salud Pública de Navarra, Fred Hutch Cancer Center, Hôpital Tenon, German Center for Diabetes Research, World Health Organization, Addenbrooke's Hospital, Translational Research Institute, USC Norris Comprehensive Cancer Center, Navarre Institute of Health Research, The Christie NHS Foundation Trust, Fundación Pública Galega de Medicina Xenómica, John Radcliffe Hospital, Centre international de recherche sur le cancer, German Institute of Human Nutrition, Andalusian School of Public Health, University Hospitals Seidman Cancer Center, University of Hawaii Cancer Center, IPO Porto, Beckman Research Institute, Cancer Council Victoria, Instituto Português de Oncologia Francisco Gentil, American Cancer Society, Cancer Research UK Cambridge Center, Stanford Cancer Institute, Hospital del Mar Research Institute, George E. Wahlen Department of VA Medical Center, The Christie Hospital, Cross Cancer Institute, International Hereditary Cancer Center, Centro de Investigação do Instituto Português de Oncologia do Porto Francisco Gentil, Health Innovation Manchester, Cancer Research UK Manchester Centre, International Epidemiology Institute